95 related articles for article (PubMed ID: 11334140)
1. Propynylated phosphodiester oligonucleotides inhibit ICAM-1 expression in A549 cells on electroporation.
Meunier L; Monsigny M; Roche AC
Antisense Nucleic Acid Drug Dev; 2001 Apr; 11(2):117-23. PubMed ID: 11334140
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects.
Hertl M; Neckers LM; Katz SI
J Invest Dermatol; 1995 May; 104(5):813-8. PubMed ID: 7738361
[TBL] [Abstract][Full Text] [Related]
3. Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo.
Kitajima I; Unoki K; Maruyama I
Antisense Nucleic Acid Drug Dev; 1999 Apr; 9(2):233-9. PubMed ID: 10355829
[TBL] [Abstract][Full Text] [Related]
4. Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells.
Li S; Deshmukh HM; Huang L
Pharm Res; 1998 Oct; 15(10):1540-5. PubMed ID: 9794495
[TBL] [Abstract][Full Text] [Related]
5. Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides.
Dheur S; Dias N; van Aerschot A; Herdewijn P; Bettinger T; Rémy JS; Hélène C; Saison-Behmoaras ET
Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):515-25. PubMed ID: 10645777
[TBL] [Abstract][Full Text] [Related]
6. Structural and immunostimulatory properties of Y-shaped DNA consisting of phosphodiester and phosphorothioate oligodeoxynucleotides.
Matsuoka N; Nishikawa M; Mohri K; Rattanakiat S; Takakura Y
J Control Release; 2010 Dec; 148(3):311-6. PubMed ID: 20887761
[TBL] [Abstract][Full Text] [Related]
7. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability.
Patzel V; Steidl U; Kronenwett R; Haas R; Sczakiel G
Nucleic Acids Res; 1999 Nov; 27(22):4328-34. PubMed ID: 10536139
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution, stability, and antiviral efficacy of liposome-entrapped phosphorothioate antisense oligodeoxynucleotides in ducks for the treatment of chronic duck hepatitis B virus infection.
Soni PN; Brown D; Saffie R; Savage K; Moore D; Gregoriadis G; Dusheiko GM
Hepatology; 1998 Nov; 28(5):1402-10. PubMed ID: 9794928
[TBL] [Abstract][Full Text] [Related]
9. ["Target secondary structural motif" in the action of antisense oligodeoxynucleotides].
Song HF; Tang ZM
Yao Xue Xue Bao; 2001 Aug; 36(8):585-9. PubMed ID: 12579934
[TBL] [Abstract][Full Text] [Related]
10. Development of antisense oligodeoxynucleotides for transplantation.
Stepkowski SM
Curr Opin Mol Ther; 2000 Jun; 2(3):304-17. PubMed ID: 11249625
[TBL] [Abstract][Full Text] [Related]
11. Optimization of antisense drug design against conservative local motif in simulant secondary structures of HER-2 mRNA and QSAR analysis.
Yang SP; Song ST; Tang ZM; Song HF
Acta Pharmacol Sin; 2003 Sep; 24(9):897-902. PubMed ID: 12956938
[TBL] [Abstract][Full Text] [Related]
12. Novel immunostimulatory phosphodiester oligodeoxynucleotides with CpT sequences instead of CpG motifs.
Kim D; Jung J; Lee Y; Kwon HJ
Mol Immunol; 2011 Jul; 48(12-13):1494-504. PubMed ID: 21529949
[TBL] [Abstract][Full Text] [Related]
13. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
Mui B; Raney SG; Semple SC; Hope MJ
J Pharmacol Exp Ther; 2001 Sep; 298(3):1185-92. PubMed ID: 11504819
[TBL] [Abstract][Full Text] [Related]
14. Sequence and chemistry requirements for a novel aptameric oligonucleotide inhibitor of EGF receptor tyrosine kinase activity.
Akhtar S; Dunnion D; Poyner D; Ackroyd J; Bibby M; Double J
Biochem Pharmacol; 2002 Jun; 63(12):2187-95. PubMed ID: 12110378
[TBL] [Abstract][Full Text] [Related]
15. Minimally modified phosphodiester antisense oligodeoxyribonucleotide directed against the multidrug resistance gene mdr1.
Brigui I; Djavanbakht-Samani T; Jollès B; Pigaglio S; Laigle A
Biochem Pharmacol; 2003 Mar; 65(5):747-54. PubMed ID: 12628488
[TBL] [Abstract][Full Text] [Related]
16. Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation.
Uhlmann E; Ryte A; Peyman A
Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):345-50. PubMed ID: 9303186
[TBL] [Abstract][Full Text] [Related]
17. Pseudo-cyclic oligonucleotides: in vitro and in vivo properties.
Jiang Z; Kandimalla ER; Zhao Q; Shen LX; DeLuca A; Normano N; Ruskowski M; Agrawal S
Bioorg Med Chem; 1999 Dec; 7(12):2727-35. PubMed ID: 10658577
[TBL] [Abstract][Full Text] [Related]
18. Quantitative evaluation of the improvement in the pharmacokinetics of a nucleic acid drug delivery system by dynamic PET imaging with (18)F-incorporated oligodeoxynucleotides.
Mukai H; Ozaki D; Cui Y; Kuboyama T; Yamato-Nagata H; Onoe K; Takahashi M; Wada Y; Imanishi T; Kodama T; Obika S; Suzuki M; Doi H; Watanabe Y
J Control Release; 2014 Apr; 180():92-9. PubMed ID: 24566256
[TBL] [Abstract][Full Text] [Related]
19. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages.
Oishi M; Nagatsugi F; Sasaki S; Nagasaki Y; Kataoka K
Chembiochem; 2005 Apr; 6(4):718-25. PubMed ID: 15756696
[TBL] [Abstract][Full Text] [Related]
20. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine.
Stewart AJ; Pichon C; Meunier L; Midoux P; Monsigny M; Roche AC
Mol Pharmacol; 1996 Dec; 50(6):1487-94. PubMed ID: 8967969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
